Completed PHASE2 INTERVENTIONAL 2-arm NCT00617461

A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment

Study PXN110527: The Investigation of the Efficacy and Pharmacokinetics of XP13512 in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN) Who Have Had an Inadequate Response to Gabapentin Treatment.

Sponsor: XenoPort, Inc.

Conditions Neuralgia, Postherpetic

Interventions GEn 1200mg/day GEn 3600mg/day

Updated 7 times since 2017 Last updated: Jul 15, 2013 Started: Mar 31, 2008 Primary completion: Jul 31, 2009 Completion: Jul 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Neuralgia, Postherpetic, this trial is completed. The trial is conducted by XenoPort, Inc. and has accumulated 7 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

XenoPort, Inc.

Data source: XenoPort, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Achim, Germany , Austin, United States , Berlin, Germany , Bochum, Germany , Bradenton, United States , Chicago, United States , Chipley, United States , Daytona Beach, United States , Decatur, United States , Dresden, Germany and 39 more locations